DeepMed Research

ALCON RESEARCH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

DuoTrav APS Versus XALACOM® in Ocular Surface Health

Phase 3

Terminated

Conditions: Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: DuoTrav APS
Drug: Xalacom

First Posted Date: 2009-06-03

Last Posted Date: 2012-07-19

Lead Sponsor: Alcon Research

Target Recruit Count: 240

Registration Number: NCT00912054

Locations: 🇧🇪
Cliniques Universitaires Saint Luc, Brussels, Belgium

An Evaluation of the Efficacy and Safety of AL-46383A Ophthalmic Solution for the Treatment of Adenoviral Conjunctivitis

Phase 2

Terminated

Conditions: Adenoviral Conjunctivitis

Interventions: Drug: AL-46383A Ophthalmic Solution
Drug: AL-46383A Ophthalmic Solution Vehicle

First Posted Date: 2009-05-14

Last Posted Date: 2014-05-22

Lead Sponsor: Alcon Research

Target Recruit Count: 452

Registration Number: NCT00901693

Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health

Phase 3

Completed

Conditions: Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost APS 40 micrograms/ml eye drop solution
Drug: Latanoprost 50 micrograms/ml eye drop solution

First Posted Date: 2009-05-05

Last Posted Date: 2014-07-15

Lead Sponsor: Alcon Research

Target Recruit Count: 434

Registration Number: NCT00892762

A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry Eye

Phase 2

Completed

Conditions: Dry Eye

Interventions: Drug: AL-38583 ophthalmic solution 0.10%
Drug: AL-38583 vehicle
Drug: AL-38583 ophthalmic solution 0.05%

First Posted Date: 2009-05-05

Last Posted Date: 2014-07-15

Lead Sponsor: Alcon Research

Target Recruit Count: 765

Registration Number: NCT00893139

Geographic Atrophy Treatment Evaluation

Phase 3

Terminated

Conditions: Age-Related Macular Degeneration
Geographic Atrophy

Interventions: Drug: AL-8309B Ophthalmic Solution
Drug: AL-8309B Vehicle

First Posted Date: 2009-04-29

Last Posted Date: 2014-07-03

Lead Sponsor: Alcon Research

Target Recruit Count: 772

Registration Number: NCT00890097

Single Site Study of the Wettability of Contact Lenses With an Investigational Multi-Purpose Disinfecting Solution vs. a Marketed Multi-Purpose Solution

Not Applicable

Completed

Conditions: Contact Lens Care

Interventions: Device: FID 114675A Multi-Purpose Disinfecting Solution (MPDS)
Device: RepleniSH Multi-Purpose Disinfecting Solution (MPDS) (OPTI-FREE® RepleniSH®)
Device: Senofilcon A contact lens (ACUVUE® Oasys™)
Device: Balafilcon A contact lens (PureVision®)

First Posted Date: 2009-04-21

Last Posted Date: 2012-03-27

Lead Sponsor: Alcon Research

Target Recruit Count: 40

Registration Number: NCT00885092

7-Day, Multi-Site Study of an Investigational Multi-Purpose Disinfecting Solution for Contact Lens Wearers

Not Applicable

Completed

Conditions: Contact Lens Care

Interventions: Device: FID 114675A Multi-Purpose Disinfecting Solution (MPDS)
Device: Etafilcon A contact lens (ACUVUE® 2™)
Device: Senofilcon A contact lens (ACUVUE® OASYS™)
Device: Lotrafilcon B contact lens (O2 OPTIX®)
Device: Balafilcon A contact lens (PureVision®)

First Posted Date: 2009-04-21

Last Posted Date: 2012-03-27

Lead Sponsor: Alcon Research

Target Recruit Count: 110

Registration Number: NCT00884806

To Evaluate the Efficacy of AL-38583 in the Reduction of Tear Eosinophil Count Following Conjunctival Allergen Challenge

Phase 2

Withdrawn

Conditions: Allergic Conjunctivitis

Interventions: Drug: AL38583 Ophthalmic Solution
Drug: Maxidex
Drug: Vehicle

First Posted Date: 2009-04-15

Last Posted Date: 2012-03-06

Lead Sponsor: Alcon Research

Registration Number: NCT00881673

Investigation of Corneal Aberrations and Visual Outcomes in Patients Implanted With an AcrySof Toric Intraocular Lens (IOL)

Not Applicable

Withdrawn

Conditions: Astigmatism
Cataracts

Interventions: Device: Toric

First Posted Date: 2009-04-09

Last Posted Date: 2012-08-02

Lead Sponsor: Alcon Research

Registration Number: NCT00878839

Travoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: Travoprost 0.004%/Timolol 0.5%
Drug: Latanoprost 0.005% / Timolol 0.5%

First Posted Date: 2009-03-31

Last Posted Date: 2013-03-28

Lead Sponsor: Alcon Research

Target Recruit Count: 242

Registration Number: NCT00872651

Locations: 🇨🇳
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy